...and recent results -
Martinsried (Germany), March 16, 2001 - GPC Biotech AG (Neuer Markt Frankfurt: GPC), a leading genomics- and proteomics-driven drug discovery company, today announced results of operations for the fiscal year ending December 31, 2000.
The Company reported that consolidated net revenues for fiscal year 2000 increased 156 % to EUR 10.9 million, from EUR 4.3 million for fiscal year 1999. The revenue growth resulted primarily from the successful commercialization of the Company’s integrated technology platform through alliances with pharmaceutical partners including Aventis Pharma, Bayer AG, the Altana AG pharmaceuticals group Byk Gulden and DuPont Pharmaceuticals Company (1).
The Company’s practice for revenue recognition from alliances has, for past years, been consistent with the transparent accounting principles now required by the US Securities and Exchange Commission’s Staff Accounting Bulletin No. 101 (SAB 101). Hence, no restatement of historical financial statements and no adjustments to projections were required and GPC Biotech incurred no extra charges as a result of this new rule.
Purchase accounting was used to account for the acquisition of Mitotix, Inc., leading to one-time charges of EUR 16.0 million in the first quarter of 2000 for acquired in-process R&D and a charge of EUR 3.7 million over last three quarters in 2000 for amortization of intangibles, none of which were cash relevant. Other one-time charges related to the acquisition total EUR 1.6 million. Non-cash one-time charges of EUR 1.2 million were incurred for in-licensing compounds from the DuPont Pharmaceuticals Company. Non-cash relevant stock options expenses amounted to EUR 2.1 million for 2000. Excluding the acquisition-related charges EBITDA & SOP (EBITDA before stock option expenses) was (EUR 13.0) million in 2000, compared to (EUR 2.5) million in 1999.
The net loss was better than management’s expectations and analysts’ consensus estimates and amounted to EUR 35.3 million for 2000, compared to a net loss of EUR 3.3 million in 1999. This translated to a loss per share (2) before acquired in-process R&D and amortization of intangible assets of EUR 1.07 compared to EUR 0.54 in 1999. Basic and diluted loss per share amounted to EUR 2.42.
The Company had EUR 108.7 million in cash and available-for-sale securities as of December 31, 2000. This provides GPC Biotech with a very strong financial position. Net cash used in operations amounted to EUR 18.5 million during 2000 (1999: EUR 0.2 million). Of the EUR 48.7 million in total expenses for the fiscal year 2000, EUR 21.0 million were non-cash relevant as the special charges detailed above had no effect on net cash used in operations.
“The year 2000 was undoubtedly the most successful year in GPC Biotech’s corporate history,” said Dr. Bernd R. Seizinger, President and CEO of GPC Biotech. “The acquisition of the US biotech company Mitotix, Inc. allowed GPC Biotech to aggressively forward-integrate to become one of the premier European biotech companies. Six additional corporate alliances through January of 2001 and the achievement of significant progress in all areas of our product programs demonstrate the strength of our integrated technology platform and our drug discovery pipeline. We successfully started into the year 2001 with new large pharmaceutical alliances with Boehringer Ingelheim International GmbH and the Altana AG subsidiary Byk Gulden. With a value of up to US$ 100 million plus royalties, our collaboration with Byk Gulden is arguably the largest pharmaceutical alliance in German biotech to date. Hence, we are well positioned for further expansion and growth.”
Key corporate highlights:
* Acquisition of the US biotech company, Mitotix, Inc., Cambridge, MA, now GPC Biotech Inc., announced on March 20, 2000 and its integration during 2000
* Successful IPO on the Neuer Markt on May 31, 2000, with gross proceeds of EUR 118.6 million
* Six new corporate alliances through mid-January 2001 with Bayer AG, Aventis Pharma, Boehringer Ingelheim International GmbH, the Altana AG subsidiary Byk Gulden, Karo Bio USA and Cytovia, Inc. (acquired by Maxim Pharmaceuticals, Inc.)
* Significant progress in the Company’s product pipeline, illustrated by scientific milestones in internal drug discovery programs
* Broadened technology platform through in-licensing of novel protein-interaction technology from California Institute of Technology and the Max Planck Society
* Initiation of commercialization of the Reverse Genomics™ platform to analyze the mode of action of potential drug candidates through an alliance with Bayer AG
* Expanded patent position with 54 issued patents and over 160 patent applications, compared to 40 issued patents and more than 120 patent applications at the time of the IPO |
